Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes.
Enclomiphene is a non-steroidal estrogen receptor antagonist that promotes gonadotropin-dependent testosterone secretion by the testes. Enclomiphene is the trans-isomer of clomiphene, which is about a 60-40 mix of trans (Enclomiphene) and cis (Zuclomiphene). While enclomiphene (trans-clomiphene) is an estrogen antagonist, zuclomiphene (cis-clomiphene) is a mixed agonist, responsible for the estrogenic activity and therefore the common side effects sometimes seen in males. The enclomiphene isomer is responsible for the anti-estrogen activity and the restoration of ones hypothalamic–pituitary–gonadal axis. In recent clinical trials, enclomiphene increased serum LH and FSH with concomitant increases in testosterone in men with secondary hypogonadism. Enclomiphene showed overall better results than testosterone gels, which raise serum testosterone but can lower LH and FSH at the same time.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 29(9), 826-829 (2013-07-17)
To evaluate the ability of a combination of multiple ovarian reserve markers to predict ovarian stimulation response in polycystic ovary syndrome (PCOS). On cycle Day 3 of 75 infertile patients with PCOS, serum follicle stimulating hormone (FSH), luteinizing hormone (LH)
Mutation research. Genetic toxicology and environmental mutagenesis, 759, 21-27 (2013-11-06)
Clomiphene citrate (CC) is a selective estrogen-receptor modulator that is primarily used to enhance follicular development in women receiving in vitro fertilization (IVF) treatment. Although some studies suggested large increases in ovarian cancer risk related to fertility medications, this association
Journal of medicine and life, 6(2), 199-201 (2013-08-02)
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women and is associated with the reproductive and metabolic disorders. To compare the ovulation and conception rates after the treatment with Clomiphene Citrate (CC) alone and in combination with metformin
Fertility and sterility, 100(2), 341-348 (2013-07-03)
This committee opinion describes the use of clomiphene citrate, including indications, use, monitoring, and side effects. There is also a discussion of adjuvants and alternatives to clomiphene citrate therapy.
Clomiphene citrate (CC) is first line treatment in women with World Health Organization (WHO) type II anovulation and polycystic ovary syndrome (PCOS). Whereas 60% to 85% of these women will ovulate on CC, only about one half will have conceived
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
